Acute toxic gastric mucosal damage induced by Lugol’s iodine spray during chromoendoscopy

Lugol’s solution, named after the French Physician JGA Lugol (1786–1851), has a high affinity for glycogen in non-keratinised squamous epithelium. Since the 1960s when Lugol’s iodine was first used to investigate esophageal diseases, advances in the field of diagnostic endoscopy have resulted in its increasing use to detect early mucosal abnormalities and to target biopsies from unstained areas. We have been performing chromoendoscopy using Lugol’s solution for the last 10 years, carrying out 10–15 procedures every year. Here we report the first case of an acute toxic reaction affecting the gastric mucosa.

At gastroscopy of a 67 year old woman with reflux symptoms, a small nodule was noted at the gastro-oesophageal junction together with reflux oesophagitis (LA grade B). Biopsies from the nodule raised the possibility of dysplasia within the squamous epithelium. One month later a repeat examination was performed to reassess the squamous epithelium and target biopsies using Lugol’s chromoendoscopy; 10 ml of 5% Lugol’s iodine was sprayed using an Olympus PL spraying catheter. Multiple biopsies were targeted to the unstained areas together with random biopsies from the distal oesophagus. At the end of the examination, the stomach was again entered to remove any stagnant iodine. The gastric mucosa underlying the pool of iodine was intensely oedematous and haemorrhagic (fig 1A, 1B) The patient did not complain of any symptoms either during or after the procedure. Gastric biopsies confirmed acute oedema of the lamina propria with loss of the superficial epithelium consistent with an acute toxic gastric mucosal injury induced by Lugol’s iodine solution (fig 1C). The oesophageal biopsies showed no dysplasia.

During a follow up examination performed three months later to reassess the lower oesophagus, the gastric mucosa appeared endoscopically and histologically unremarkable. Chromoendoscopy using Lugol’s solution is not without hazards. Local irritation of the oesophageal mucosa may cause retrosternal pain. General allergic reactions include laryngospasm, bronchospasm, and even cardiac arrest. The concentration of the solution used in studies ranges from 0.5% to 5%, and higher concentrations (3–5%) may be associated with a higher risk of complications. A Japanese study reported that washing the mucosa with sodium thiosulphate may neutralise the iodine solution and reduce retrosternal discomfort. Only two cases of gastric mucosal erosions have been reported after the application of iodine.

In this case, the histological features of localised oedema and loss of superficial gastric epithelium in the absence of significant inflammatory cell infiltrate supported an acute toxic injury to the gastric mucosa. The toxic reaction was confined to the columnar epithelium in the greater curve of the stomach that was in direct contact with the pooled 5% Lugol’s iodine while the squamous oesophageal mucosa remained unremarkable both endoscopically and histologically. Gastric columnar epithelium may be more susceptible to the toxic effect of Lugol’s iodine and mucosal injury may go unrecognized unless the stomach is re-examined after application of the dye. To reduce the risks, we now use 10–20 ml of 1.5% Lugol’s solution and routinely aspirate the gastric pool before assessing the oesophageal mucosa.

Previous studies have shown that Lugol’s staining is useful in screening for early oesophageal cancer in high risk populations such as patients with previous or current non-oesophageal malignancy and those with a high alcohol intake. However, none of these studies commented on the adverse reactions to Lugol’s staining during endoscopy. We suggest that the adverse reactions and safety profile of iodine staining need to be addressed, in particular before recommending its routine use for screening purposes. Also, where it has to be used, a lower concentration of 1.5% may be less toxic to the gastric mucosa and is thus recommended.

LETTERS

Acute toxic gastric mucosal damage induced by Lugol’s iodine spray during chromoendoscopy

Physician JGA Lugol (1786–1851), has a high affinity for glycogen in non-keratinised squamous epithelium. Since the 1960s when Lugol’s iodine was first used to investigate esophageal diseases, advances in the field of diagnostic endoscopy have resulted in its increasing use to detect early mucosal abnormalities and to target biopsies from unstained areas. We have been performing chromoendoscopy using Lugol’s solution for the last 10 years, carrying out 10–15 procedures every year. Here we report the first case of an acute toxic reaction affecting the gastric mucosa.

At gastroscopy of a 67 year old woman with reflux symptoms, a small nodule was noted at the gastro-oesophageal junction together with reflux oesophagitis (LA grade B). Biopsies from the nodule raised the possibility of dysplasia within the squamous epithelium. One month later a repeat examination was performed to reassess the squamous epithelium and target biopsies using Lugol’s chromoendoscopy; 10 ml of 5% Lugol’s iodine was sprayed using an Olympus PL spraying catheter. Multiple biopsies were targeted to the unstained areas together with random biopsies from the distal oesophagus. At the end of the examination, the stomach was again entered to remove any stagnant iodine. The gastric mucosa underlying the pool of iodine was intensely oedematous and haemorrhagic (fig 1A, 1B) The patient did not complain of any symptoms either during or after the procedure. Gastric biopsies confirmed acute oedema of the lamina propria with loss of the superficial epithelium consistent with an acute toxic gastric mucosal injury induced by Lugol’s iodine solution (fig 1C). The oesophageal biopsies showed no dysplasia.

During a follow up examination performed three months later to reassess the lower oesophagus, the gastric mucosa appeared endoscopically and histologically unremarkable. Chromoendoscopy using Lugol’s solution is not without hazards. Local irritation of the oesophageal mucosa may cause retrosternal pain. General allergic reactions include laryngospasm, bronchospasm, and even cardiac arrest. The concentration of the solution used in studies ranges from 0.5% to 5%, and higher concentrations (3–5%) may be associated with a higher risk of complications. A Japanese study reported that washing the mucosa with sodium thiosulphate may neutralise the iodine solution and reduce retrosternal discomfort. Only two cases of gastric mucosal erosions have been reported after the application of iodine.

In this case, the histological features of localised oedema and loss of superficial gastric epithelium in the absence of significant inflammatory cell infiltrate supported an acute toxic injury to the gastric mucosa. The toxic reaction was confined to the columnar epithelium in the greater curve of the stomach that was in direct contact with the pooled 5% Lugol’s iodine while the squamous oesophageal mucosa remained unremarkable both endoscopically and histologically. Gastric columnar epithelium may be more susceptible to the toxic effect of Lugol’s iodine and mucosal injury may go unrecognized unless the stomach is re-examined after application of the dye. To reduce the risks, we now use 10–20 ml of 1.5% Lugol’s solution and routinely aspirate the gastric pool before assessing the oesophageal mucosa.

Previous studies have shown that Lugol’s staining is useful in screening for early oesophageal cancer in high risk populations such as patients with previous or current non-oesophageal malignancy and those with a high alcohol intake. However, none of these studies commented on the adverse reactions to Lugol’s staining during endoscopy. We suggest that the adverse reactions and safety profile of iodine staining need to be addressed, in particular before recommending its routine use for screening purposes. Also, where it has to be used, a lower concentration of 1.5% may be less toxic to the gastric mucosa and is thus recommended.

A Sreedharan, B J Rembacken
Department of Gastroenterology, The General Infirmary at Leeds, Leeds, UK

O Rotini
Department of Histopathology, The General Infirmary at Leeds, Leeds, UK

B J Rembacken
Department of Gastroenterology, The General Infirmary at Leeds, Leeds, UK

Correspondence to: Dr B J Rembacken, Department of Gastroenterology, The General Infirmary at Leeds, Great George Street, Leeds LS1 3EX, UK; bjr@ffi sme.co.uk
doi: 10.1136/gut.2004.061739

Conflict of interest: None declared.

References
Erosions or not in GORD? The potential role of oesophageal cell proliferation

Gastro-oesophageal reflux is an almost universal daily occurrence, but only a small percentage of the population develops gastro-oesophageal reflux disease (GORD) and, among them, a small number develop erosive oesophagitis (ERD) or one of its complications. It is well accepted that the pathophysiology of GORD is related to failure of antireflux mechanisms but several phenomena are not fully explained on the basis of this sequence. There is no apparent relation between damage and the amount and quality of refluxate. It is not known why the same amount of refluxate determines GORD in one patient and not in another. It is also unclear whether there is a relation between unexplained questions and the possible influence of proliferative responses of epithelial proliferating cells to damage. Hence we evaluated cell proliferation of the oesophageal epithelium using Ki67 immunostaining in normal subjects and in patients with GORD, with or without erosions.

Patients gave written informed consent to participate in the study which was approved by the ethics committee. The design was blinded for epithelial cell kinetic evaluation. Thirty five subjects were enrolled: nine were healthy voluntary controls with normal pH testing and normal endoscopic, histological, and ultrastructural patterns. Twenty six patients were affected by GORD, defined as frequent heartburn for at least a year, and abnormal 24 hour pH, histological, and ultrastructural parameters. Of these 26 patients, 13 had a normal appearing oesophageal mucosa at endoscopy (NERD) while 13 had ERD (table 1).

All subjects underwent gastroscopy; six biopsies were obtained within the lower 5 cm of the oesophagus from areas of macroscopically intact oesophageal mucosa. The presence of oesophagitis was graded according to the Los Angeles classification.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Demographic, endoscopic, pH monitoring, histological, and ultrastructural data of the studied population (normal healthy controls, and gastro-oesophageal reflux disease patients with erosive oesophagitis (ERD) and those with a normal appearing oesophageal mucosa (NERD))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>NERD</td>
</tr>
<tr>
<td>No of subjects</td>
<td>9</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>4/5</td>
</tr>
<tr>
<td>Age (y) (mean (SD) 38.67 (17.36) 41.62 (11.77) 42.54 (13.33))</td>
<td>26–63</td>
</tr>
<tr>
<td>% Time oesophageal pH &lt; 4</td>
<td>5.42 (1.1)</td>
</tr>
<tr>
<td>Endoscopy</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>D</td>
</tr>
<tr>
<td>Histology</td>
<td>Normal</td>
</tr>
<tr>
<td></td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td>TEM value (mean (SD))</td>
<td>0.54 (0.08)</td>
</tr>
</tbody>
</table>

TEM, transmission electron microscopy.

p < 0.001

References

Role of IL-10 promoter haplotypes in Helicobacter pylori associated gastric inflammation

We read with great interest the article by Rad et al (Gut 2004;53:1082–9) on the influence of cytokine gene polymorphisms on mucosal cytokine expression, gastric inflammation, and host specific colonization in Helicobacter pylori infection. The authors reported an association of the constraining inflammatory interleukin 10 (IL-10) promoter haplotype (GCC) with higher mucosal mRNA levels and colonization with more virulent cagA+, vacA+ STRs in 207 patients with H pylori infected chronic gastritis. Rad et al identified pathogenicity genes of H pylori isolates by polymerase chain reaction based techniques from gastric biopsies.

However, the human stomach is colonised by more than one strain of H pylori, which obscures the investigation of germline mutations and host specific colonization.1 Moreover, within an apparently homogenous population, remarkable genetic differences exist among single colony isolates. The capacity of H pylori to lose and possibly acquire exogenous DNA is consistent with a model of continuous microevolution within Helicobacter pylori. The capacity of H pylori to lose and possibly acquire exogenous DNA is consistent with a model of continuous microevolution within Helicobacter pylori. The endoscopic assessment of esophagitis: a progress report on an observer agreement. Gastroenterology 1996;111:1558–9.


3 Role of IL-10 promoter haplotypes in Helicobacter pylori associated gastric inflammation

We read with great interest the article by Rad et al (Gut 2004;53:1082–9) on the influence of cytokine gene polymorphisms on mucosal cytokine expression, gastric inflammation, and host specific colonization in Helicobacter pylori infection. The authors reported an association of the constraining inflammatory interleukin 10 (IL-10) promoter haplotype (GCC) with higher mucosal mRNA levels and colonization with more virulent cagA+, vacA+ strains in 207 patients with H pylori infected chronic gastritis. Rad et al identified pathogenicity genes of H pylori isolates by polymerase chain reaction based techniques from gastric biopsies.

However, the human stomach is colonised by more than one strain of H pylori, which obscures the investigation of germline mutations and host specific colonization.1 Moreover, within an apparently homogenous population, remarkable genetic differences exist among single colony isolates. The capacity of H pylori to lose and possibly acquire exogenous DNA is consistent with a model of continuous microevolution within Helicobacter pylori. The capacity of H pylori to lose and possibly acquire exogenous DNA is consistent with a model of continuous microevolution within Helicobacter pylori. The endoscopic assessment of esophagitis: a progress report on an observer agreement. Gastroenterology 1996;111:1558–9.


Table 1 Haplotype analysis of the interleukin 10 (IL-10) promoter in 440 patients with chronic gastritis and gastric ulcer disease

<table>
<thead>
<tr>
<th>IL-10 promoter</th>
<th>Chronic gastritis (n = 316)</th>
<th>Gastric ulcer (n = 124)</th>
<th>OR</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>−1082</td>
<td>G</td>
<td>48.0%</td>
<td>48.3%</td>
<td>1.01</td>
</tr>
<tr>
<td>−819</td>
<td>C</td>
<td>23.6%</td>
<td>24.2%</td>
<td>1.03</td>
</tr>
<tr>
<td>−592</td>
<td>A</td>
<td>28.2%</td>
<td>27.5%</td>
<td>0.97</td>
</tr>
</tbody>
</table>

OR, odds ratio.

Gastric ulceration due to chronic mesenteric ischaemia treated by stenting of the inferior mesenteric artery

We report a case of gastric ulceration due to visceral ischaemia treated successfully by stenting of the inferior mesenteric artery (IMA) alone. Gastric ulceration has rarely been described as a complication of chronic mesenteric ischaemia.[1–3] Four of the five cases described in these reports were treated surgically and one by angioplasty to the superior mesenteric artery (SMA). All were reported to have successful resolution of gastric ulcers. To our knowledge, there is no other case of successful stenting of the IMA alone, with resolution of gastric ischaemia described in the medical literature.

Our patient was a 50 year old woman presenting with abdominal pain, loss of appetite, vomiting, and weight loss. Pain was maximal in the epigastrium and precipitated by meals. Apart from being a smoker there was no other significant medical history. She was empirically started on omeprazole. Oesophagogastroduodenoscopy (OGD) revealed multiple serpiginous ulcers affecting the body of the stomach with extension to the cardia (fig 1D). Histology from the ulcers demonstrated ulceration with regenerative hyperplasia with no evidence of Helicobacter pylori infection. An abdominal computed tomography scan showed non-specific thickening of the pylorus and first part of the duodenum but was otherwise normal. A small bowel follow through revealed no abnormality.

Fasting gut hormone levels, including gastrin level, after stopping omeprazole were normal and a vasculitis screen (including serum ANCA) was negative.

Her abdominal pain was controlled by morphine 120 mg/day. A repeat OGD 10 weeks after treatment with omeprazole 40 mg once daily showed continuing ulceration with no improvement since the previous examination. Further histology showed similar findings as before.

Abdominal angiography demonstrated complete occlusion of the SMA origin (fig 1B), and tight ostial stenoses of the IMA (fig 1A) and coeliac axis. The SMA branches filled sluggishly and were reconstituted almost exclusively via the left colic branch of the IMA.

Attempts to bypass the coeliac axis stenosis and proximal SMA occlusion were
The interest in this case lies in the fact that only the IMA needed to be stented to achieve an appropriate vascular supply to the stomach, despite severe obstructions and reduced flow in the coeliac and mesenteric axes. This has not been described before, and demonstrates that minimally invasive radiological stenting of only one territory of the mesenteric axis, even the IMA alone, can provide enough blood flow to treat the complications of chronic mesenteric vascular disease. This case is a reminder that chronic mesenteric vascular disease should be considered as a cause of resistant gastric ulceration. This case also demonstrates that minimally invasive radiological stenting of only one territory of the mesenteric axis, even the IMA alone, can provide enough blood flow to treat the complications of chronic mesenteric vascular disease.

Diagnostic radiation exposure and cancer risk

Diagnostic and therapeutic radiological investigations are an essential part of the workup of patients with a number of clinical problems across a variety of medical specialties. Although new non-x ray technologies have started to replace traditional investigations these have not lead to a reduction in radiation exposure. In contrast, based on global statistics and projections, radiation exposure of patients is increasing, in particular as a result of new indications and use in cross sectional imaging.

In addition, multiple investigations of patients with chronic disease can lead to substantial individual radiation exposure as surgical practice increasingly relies on the use of cross sectional imaging to aid diagnosis and treatment. New imaging techniques, in particular computed tomography (CT) colonography, have become attractive alternatives to conventional colonoscopy. However, the necessity for both prone and supine scanning means that radiation exposure is double that of a conventional abdominal scan which can lead to a theoretical increase in the risk of exposure related cancer and death.

The awareness of hospital doctors about radiation exposure and associated cancer risk is poor. From personal experience, many gastroenterologists involved in diagnostic and therapeutic procedures using ionising radiation do not routinely wear full protective clothing (0.35 mm lead equivalent aprons, thyroid shield, lead glasses) on a regular basis. This is also shown in a survey of endoscopic retrograde cholangiopancreatography (ERCP) practices by Campbell et al in which only 52% of respondents reported wearing a thyroid shield all of the time.

An audit of radiation exposure to personnel performing ERCP found that both patients and staff are exposed to significant radiation exposure. This was equivalent to an estimated additional lifetime fatal cancer risk of between 1 in 3500 and 1 in 7000. These studies highlight the substantial underestimation by medical staff of patient and operator related radiation induced cancer risk.

The National Radiological Protection Board (NRPB) has recently revised the radiation dose for typical x ray examinations. For example, an abdominal/pelvic CT scan would be estimated to be up to five times higher for countries with a higher use of diagnostic x rays. The British Society of Radiology has made specific recommendations to reduce radiation exposure. Adherence to these guidelines may well be an explanation for the comparatively low frequency of diagnostic x ray in UK practice.

Clinicians should use these recommendations when considering radiological investigations. Protection of operators and nursing staff using recommended protective clothing should also be followed. Change in clinical practice may not be easy to achieve as, for example, endoscopic capacity to reduce the number of alternative radiological investigations, such as barium enema is limited. In contrast, barium enemas are often used to reduce the demand on endoscopic services. New technologies and methods may well reduce radiation exposure. Examples in gastroenterology include magnetic resonance cholangiopancreatography or endoscopic ultrasound instead of ERCP and magnetic resonance enteroclysis instead of small bowel enema. Technologies advance, in particular low dose helical CT could further reduce radiation exposure by 40–70%. However, availability of these technologies is limited or only slowly increasing and it is therefore unlikely that their use will influence radiation exposure in the near future.

What remains is the judicious use of radiological investigations and close liaison with radiologists in order to keep the radiation exposure of patients and staff as low as possible.

V K Patel, I Barrison
Hemel Hempstead General Hospital, Hemel Hempstead, Hertfordshire, UK

J Jackson
Hammersmith Hospital, London, UK

S Catnach
Hemel Hempstead General Hospital, Hemel Hempstead, Hertfordshire, UK

Correspondence to: Dr S Catnach, Hemel Hempstead General Hospital, Hillfield Rd, Hemel Hempstead, Hertfordshire HP2 4AD, UK; susan.catnach@whht.nhs.uk

doi: 10.1136/gut.2004.063248

Conflict of interest: None declared.

Figure 1

(A) Inferior mesenteric artery (IMA) stenosis, (B) superior mesenteric artery occlusion, (C) stented IMA, and (D) gastric ulcer.

Diagnostic and therapeutic radiological investigations are an essential part of the workup of patients with a number of clinical problems across a variety of medical specialties. Although new non-x ray technologies have started to replace traditional investigations these have not lead to a reduction in radiation exposure. In contrast, based on global statistics and projections, radiation exposure of patients is increasing, in particular as a result of new indications and use in cross sectional imaging. In addition, multiple investigations of patients with chronic disease can lead to substantial individual radiation exposure as surgical practice increasingly relies on the use of cross sectional imaging to aid diagnosis and treatment. New imaging techniques, in particular computed tomography (CT) colonography, have become attractive alternatives to conventional colonoscopy. However, the necessity for both prone and supine scanning means that radiation exposure is double that of a conventional abdominal scan which can lead to a theoretical increase in the risk of exposure related cancer and death.

The awareness of hospital doctors about radiation exposure and associated cancer risk is poor. From personal experience, many gastroenterologists involved in diagnostic and therapeutic procedures using ionising radiation do not routinely wear full protective clothing (0.35 mm lead equivalent aprons, thyroid shield, lead glasses) on a regular basis. This is also shown in a survey of endoscopic retrograde cholangiopancreatography (ERCP) practices by Campbell et al in which only 52% of respondents reported wearing a thyroid shield all of the time. An audit of radiation exposure to personnel performing ERCP found that both patients and staff are exposed to significant radiation exposure. This was equivalent to an estimated additional lifetime fatal cancer risk of between 1 in 3500 and 1 in 7000. These studies highlight the substantial underestimation by medical staff of patient and operator related radiation induced cancer risk.

The National Radiological Protection Board (NRPB) has recently revised the radiation dose for typical x ray examinations. For example, an abdominal/pelvic CT scan would be estimated to be up to five times higher for countries with a higher use of diagnostic x rays. The British Society of Radiology has made specific recommendations to reduce radiation exposure. Adherence to these guidelines may well be an explanation for the comparatively low frequency of diagnostic x ray in UK practice. Clinicians should use these recommendations when considering radiological investigations. Protection of operators and nursing staff using recommended protective clothing should also be followed. Change in clinical practice may not be easy to achieve as, for example, endoscopic capacity to reduce the number of alternative radiological investigations, such as barium enema is limited. In contrast, barium enemas are often used to reduce the demand on endoscopic services. New technologies and methods may well reduce radiation exposure. Examples in gastroenterology include magnetic resonance cholangiopancreatography or endoscopic ultrasound instead of ERCP and magnetic resonance enteroclysis instead of small bowel enema. Technologies advance, in particular low dose helical CT could further reduce radiation exposure by 40–70%. However, availability of these technologies is limited or only slowly increasing and it is therefore unlikely that their use will influence radiation exposure in the near future.

What remains is the judicious use of radiological investigations and close liaison with radiologists in order to keep the radiation exposure of patients and staff as low as possible.

V K Patel, I Barrison
Hemel Hempstead General Hospital, Hemel Hempstead, Hertfordshire, UK

J Jackson
Hammersmith Hospital, London, UK

S Catnach
Hemel Hempstead General Hospital, Hemel Hempstead, Hertfordshire, UK

Correspondence to: Dr S Catnach, Hemel Hempstead General Hospital, Hillfield Rd, Hemel Hempstead, Hertfordshire HP2 4AD, UK; susan.catnach@whht.nhs.uk

doi: 10.1136/gut.2004.063248

Conflict of interest: None declared.

Figure 1

(A) Inferior mesenteric artery (IMA) stenosis, (B) superior mesenteric artery occlusion, (C) stented IMA, and (D) gastric ulcer.

Diagnostic and therapeutic radiological investigations are an essential part of the workup of patients with a number of clinical problems across a variety of medical specialties. Although new non-x ray technologies have started to replace traditional investigations these have not lead to a reduction in radiation exposure. In contrast, based on global statistics and projections, radiation exposure of patients is increasing, in particular as a result of new indications and use in cross sectional imaging. In addition, multiple investigations of patients with chronic disease can lead to substantial individual radiation exposure as surgical practice increasingly relies on the use of cross sectional imaging to aid diagnosis and treatment. New imaging techniques, in particular computed tomography (CT) colonography, have become attractive alternatives to conventional colonoscopy. However, the necessity for both prone and supine scanning means that radiation exposure is double that of a conventional abdominal scan which can lead to a theoretical increase in the risk of exposure related cancer and death.

The awareness of hospital doctors about radiation exposure and associated cancer risk is poor. From personal experience, many gastroenterologists involved in diagnostic and therapeutic procedures using ionising radiation do not routinely wear full protective clothing (0.35 mm lead equivalent aprons, thyroid shield, lead glasses) on a regular basis. This is also shown in a survey of endoscopic retrograde cholangiopancreatography (ERCP) practices by Campbell et al in which only 52% of respondents reported wearing a thyroid shield all of the time. An audit of radiation exposure to personnel performing ERCP found that both patients and staff are exposed to significant radiation exposure. This was equivalent to an estimated additional lifetime fatal cancer risk of between 1 in 3500 and 1 in 7000. These studies highlight the substantial underestimation by medical staff of patient and operator related radiation induced cancer risk.

The National Radiological Protection Board (NRPB) has recently revised the radiation dose for typical x ray examinations. For example, an abdominal/pelvic CT scan would be estimated to be up to five times higher for countries with a higher use of diagnostic x rays. The British Society of Radiology has made specific recommendations to reduce radiation exposure. Adherence to these guidelines may well be an explanation for the comparatively low frequency of diagnostic x ray in UK practice. Clinicians should use these recommendations when considering radiological investigations. Protection of operators and nursing staff using recommended protective clothing should also be followed. Change in clinical practice may not be easy to achieve as, for example, endoscopic capacity to reduce the number of alternative radiological investigations, such as barium enema is limited. In contrast, barium enemas are often used to reduce the demand on endoscopic services. New technologies and methods may well reduce radiation exposure. Examples in gastroenterology include magnetic resonance cholangiopancreatography or endoscopic ultrasound instead of ERCP and magnetic resonance enteroclysis instead of small bowel enema. Technologies advance, in particular low dose helical CT could further reduce radiation exposure by 40–70%. However, availability of these technologies is limited or only slowly increasing and it is therefore unlikely that their use will influence radiation exposure in the near future.

What remains is the judicious use of radiological investigations and close liaison with radiologists in order to keep the radiation exposure of patients and staff as low as possible.

M B Frenz, A S Mee
Department of Gastroenterology, Royal Berkshire Hospital, London Rd, Reading, UK

Correspondence to: Dr A S Mee, Department of Gastroenterology, Royal Berkshire Hospital, London Rd, Reading RG1 5AN, UK; anthony.mee@rbhb-tr.nhs.uk

doi: 10.1136/gut.2005.066605

Conflict of interest: None declared.

References


2 Rosen MP, Stiewert B, Sands DZ, et al. Value for abdominal CT in the emergency department for


Adalimumab use in pregnancy

Infliximab, a chimeric antibody to tumour necrosis factor alpha (TNF-α), has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease. Antibodies to the chimeric component of infliximab can lead to infusion reactions and possible loss of response. A human recombinant monoclonal antibody to TNF-α, adalimumab, has recently demonstrated safety and efficacy for induction of remission in Crohn’s disease. It has also been effective in patients who have lost response to infliximab. Currently, this drug is FDA approved for the treatment of rheumatoid arthritis but it is being administered off label to patients with Crohn’s disease who are intolerant of infliximab. The safety profile during pregnancy is not well known for either drug. We report a patient who has had two successful pregnancies, one while on infliximab and the other while on adalimumab.

A 34 year old woman with longstanding ileocolonic and perianal Crohn’s disease had severe disease activity at the time of conception. She had been on mesalamine, budesonide, and prednisone, and was unable to attain remission. She was intolerant of purine analogues, infliximab had been successful in the past but she lost response over time. Adalimumab was started and she was on a maintenance regimen approximately one month prior to conception. During her pregnancy, she received a total of 38 doses of adalimumab at 40 mg subcutaneously every week. She continued on adalimumab following delivery and breast fed while on the drug. She had severely active disease at conception but had mild improvement by the first trimester and had moderately active disease throughout the third trimester. Postpartum, she had mild to inactive disease. She successfully tapered her prednisone from 15 mg daily to 2.5 mg every other day by one month post partum. The pregnancy was uncomplicated and surveillance sonograms revealed normal growth without visible congenital anomalies. Due to a history of perianal disease, an elective Caesarean section was performed without complications at 38.5 weeks. No neo-natal abnormalities were noted, and APGAR scores were 8 and 9. The child is now six months with normal growth and development.

This case is the first report of maintenance adalimumab use during pregnancy. With infliximab, animal studies for treatment of rheumatoid arthritis have not revealed fetotoxicity or teratogenicity. Katz et al reported on 96 human pregnancies exposed to infliximab with known outcomes. Of 100 progency, 69 were live births, 13 were miscarriages, and 18 were elective terminations. This is similar to what is expected in the general Crohn’s population. We reported 10 women who had maintained infliximab use during pregnancy: all ended in live births with three premature infants and one with low birth weight.

While the health of the mother is our priority as gastroenterologists, the safety of inflammatory bowel disease medications during the childbearing years is always of concern. As biological agents are increasingly being used for maintenance therapy in Crohn’s disease, more patients are healthy enough to consider conception. Careful data collection and prospective study is required to be able to guide the management of men and women with inflammatory bowel disease desiring conception to ensure the health of the parent and child.

V L Esca, JP Terduman, U Mahadevan
Division of Gastroenterology, University of California, San Francisco, USA

Correspondence to: Dr U Mahadevan, MD, Division of Gastroenterology, University of California, 2330 Post Street, #410, San Francisco, CA 94115, USA; umamah@itsa.ucsf.edu

doi: 10.1136/gut.2005.065417

Conflict of interest: declared (the declaration can be viewed on the Gut website at http://www.gut.com/supplemental/).

References


Can gastro-oesophageal reflux be predicted while advancing the endoscope through the laryngeal area?

We read with great interest the article by Mullhaupt et al regarding examination of the laryngopharyngeal area during gastro-intestinal endoscopy, after being trained for examination of these anatomical structures (Gut 2004;53:1232–4). Twenty six laryngeal pathologies were discovered in 1311 cases, the most important of which was demonstration of an early supraglottic cancer. Upper gastrointestinal endoscopy has been performed in children for various indications. In paediatric gastroenterology practice, endoscopy is an important procedure beginning from the mouth. After inserting the endoscope through the oral cavity, the uvula, epiglottis, and cricoarytenoid cartilages with the vocal cords above are seen. While passing through the epiglottic area, the concomitant laryngitis, oedema, hyperaemia or ulceration of the arytenoids, and laryngeal granulomas can be visualised. Examination of the laryngopharyngeal area is not a routine part of the endoscopic procedure in children.

Although supraglottic cancer is extremely rare among children, a more common problem of the laryngeal area during childhood is gastro-oesophageal reflux (GOR), which affects almost 10% of children. Recurrent upper or lower respiratory tract infections, and weight loss are frequent clinical findings with GOR. Extraoesophageal manifestations of GOR have been identified and recognised more recently in the past decade. The phrase “extraoesophageal reflux” refers to the effects of refluxed gastric material far from the oesophagus. It has been shown that the contents of the gastric juice, including hydrochloric acid and pepsin, are damaging not only to the oesophagus but also to pharyngeal and laryngeal tissues. Resistance of the laryngeal mucosa to refluxed gastric contents during upper oesophageal swallowing is an important factor predicting the severity of laryngeal injury. Garvey and colleagues reported the otolaryngological manifestations of gastro-oesophageal reflux disease, stated that the presence of erythema, oedema of the arytenoids and posterior part of the vocal cords, or more chronic changes such as the presence of granulomas might suggest GOR in patients with dysphagia.

In our paediatric gastroenterology outpatient clinic, 375 upper gastrointestinal endoscopies were performed in children aged...
Is stool DNA multitarget testing an unreliable strategy for colorectal cancer screening?

The availability of a simple non-invasive test capable of detecting colorectal cancer specific products with reasonable sensitivity and specificity might avoid the invasiveness, unpleasant bowel preparation, and risk of bleeding and perforation related to colonoscopy. Molecular marker combinations in faecal DNA testing have been shown to produce high rates of both colorectal cancer and advanced adenoma detection in selected patient populations, and observations from large representative groups are emerging. Imperiale and colleagues have recently reported the results of the first large study of faecal DNA testing in asymptomatic subjects. A total of 4404 average risk adults, who were at least 50 years old, underwent faecal occult blood testing, faecal DNA testing, and colonoscopy, which was considered the reference standard. Comparing test results in a random subgroup of 2507 persons, the authors found that the faecal DNA test was much more sensitive than faecal occult blood testing in detecting colorectal cancer and adenomas with high grade dysplasia. However, the sensitivity for both the faecal DNA panel and faecal occult blood testing was low. In particular, the faecal DNA test detected only 52% of colorectal cancers and 15% of adenomas, rates that were far lower than those previously reported in the literature for multitarget testing. Furthermore, in the same study, the sensitivity of faecal occult blood testing (13%) was unexpectedly low.

Interestingly, in the results section, Imperiale and colleagues reported that “among 1423 subjects with negative findings on colonoscopy, 79 had a positive faecal DNA panel and 0 had a positive Faecal occult blood test, for specificities of 94.4% and 95.2%, respectively”. The question immediately arises as to whether these patients subsequently developed “advanced neoplasia” or “advanced polyps” and consequently whether the results from the DNA stool test or faecal occult blood test were falsely or truly positive. In fact, colonoscopy could have produced false negative results for several reasons, including misinterpretation of what was visualised or failure to perform adequate biopsy of the lesions seen. In this case, it could be intriguing to compare the ability of faecal DNA panel versus that of the Hemoccult II test in predicting the early occurrence of “advanced neoplasia” when colonoscopy misses the disease.

CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems

We read with great interest the paper by Gao et al, where the authors elegantly proved the efficacy of a CD40 antisense oligonucleotide for the treatment of trinitrobenzene sulphonic acid (TNBS) induced colitis in rats (Gut 2009;58:70–7). Their results are in keeping with previous reports in which immune-blockade of CD40 ligand (L) was also able to ameliorate experimental colitis. The authors conclude that interruption of inter-actions between CD40 bearing monocytes and endothelial cells and CD40 positive T cells is crucial for the beneficial effect exerted by CD40 antisense oligonucleotide in TNBS induced experimental colitis.

In the past few years we have been investigating the role of the CD40/CD40L pathway in the pathogenesis of inflammatory bowel disease (IBD). We and others have recently shown that, apart from endothelial cells and monocytes, human intestinal fibroblasts (HIF) also express the CD40 surface. HIF significantly upregulate CD40 expression, both at the mucosal and sub-mucosal levels, in patients with active IBD. Moreover, we and others have shown that coloqure of CD40 expressing HIF with CD40L T cells induces fibroblast activation, leading to chemokine and cytokine production, cell adhesion molecule upregulation, and activation of the intracellular signalling machinery, by triggering MAP kinases and nuclear factor β activation. All of these events are biologically relevant for the inflammatory process as fibroblast derived chemokines mediate T cell recruitment. Another intriguing observation is the demonstration that CD40L T cells modulate collagen synthesis by HIF, thus suggesting the potential involvement of the CD40/CD40L pathway in stricture formation in Crohn’s disease (CD). Therefore, blockade of HIF CD40 is another potential mechanism for the therapeutic efficacy of CD40 antisense.

We have also shown that platelets express high levels of biologically active surface CD40 in a constitutive manner. This molecule provides a novel pathway for platelet activation, as shown by the observation of RANTES release after platelet stimulation. These events are particularly relevant at sites of intense immune activation where local inflamed endothelial cells retain RANTES on their surface and mediate T cell adhesion, thus locally amplifying the inflammatory response. Moreover, various scientists recently showed that the CD40/CD40L system also plays a critical role in mediating platelet adhesion to and activation of intestinal microvasculature or leucocytes. Gao et al (Gut 2009;58:70–7) suggest that CD40L positive T cells could stimulate CD40 endothelium, and that CD40 antisense could prevent such cell interactions. Recently, we

References


Conflict of interest: None declared.

CD40 antisense based strategy for inflammatory bowel disease: shutting down multiple cellular communication systems

We read with great interest the paper by Gao et al, where the authors elegantly proved the efficacy of a CD40 antisense oligonucleotide for the treatment of trinitrobenzene sulphonic acid (TNBS) induced colitis in rats (Gut 2009;58:70–7). Their results are in keeping with previous reports in which immune-blockade of CD40 ligand (L) was also able to ameliorate experimental colitis. The authors conclude that interruption of inter-actions between CD40 bearing monocytes and endothelial cells and CD40 positive T cells is crucial for the beneficial effect exerted by CD40 antisense oligonucleotide in TNBS induced experimental colitis.

In the past few years we have been investigating the role of the CD40/CD40L pathway in the pathogenesis of inflammatory bowel disease (IBD). We and others have recently shown that, apart from endothelial cells and monocytes, human intestinal fibroblasts (HIF) also express the CD40 surface. HIF significantly upregulate CD40 expression, both at the mucosal and sub-mucosal levels, in patients with active IBD. Moreover, we and others have shown that coloqure of CD40 expressing HIF with CD40L T cells induces fibroblast activation, leading to chemokine and cytokine production, cell adhesion molecule upregulation, and activation of the intracellular signalling machinery, by triggering MAP kinases and nuclear factor β activation. All of these events are biologically relevant for the inflammatory process as fibroblast derived chemokines mediate T cell recruitment. Another intriguing observation is the demonstration that CD40L T cells modulate collagen synthesis by HIF, thus suggesting the potential involvement of the CD40/CD40L pathway in stricture formation in Crohn’s disease (CD). Therefore, blockade of HIF CD40 is another potential mechanism for the therapeutic efficacy of CD40 antisense.

We have also shown that platelets express high levels of biologically active surface CD40 in a constitutive manner. This molecule provides a novel pathway for platelet activation, as shown by the observation of RANTES release after platelet stimulation. These events are particularly relevant at sites of intense immune activation where local inflamed endothelial cells retain RANTES on their surface and mediate T cell adhesion, thus locally amplifying the inflammatory response. Moreover, various scientists recently showed that the CD40/CD40L system also plays a critical role in mediating platelet adhesion to and activation of intestinal microvasculature or leucocytes. Gao et al (Gut 2009;58:70–7) suggest that CD40L positive T cells could stimulate CD40 endothelium, and that CD40 antisense could prevent such cell interactions. Recently, we

References


have described that apart from T cells, activated platelet also express CD40L. Platelets display enhanced levels of membrane bound CD40L in CD and ulcerative colitis patients, and secrete higher amounts of soluble CD40L, compared with healthy controls. These phenomena have biological relevance in terms of intestinal microvascular activation as IBD activated platelets trigger chemokine production, VCAM-1, ICAM-1, and CD40L upregulation, and T cell adhesion to the gut endothelium. Therefore, abrogation of endothelial or platelet CD40 expression would not only block T cell-endothelial interactions but also interrupt platelet-endothelial and platelet-leucocyte cell cross-talk in the gut microvasculature.

Taken together, these observations suggest that the CD40 antisense oligonucleotide used by Gao et al exerts its beneficial effect not only by disrupting the interaction between CD40 bearing monocytes and endothelial cells and CD40L positive T cells, but also by acting on a much wider array of cell types able to express either CD40 or CD40L. We conclude that the use of CD40 antisense oligonucleotides appears to be a very promising therapeutic approach to turn off intestinal inflammation, by disconnecting a crucial and almost ubiquitous communication system used by multiple cell types during inflammation.

S Danese
Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy

M Sans
Division of Gastroenterology, Hospital Clinic, Barcelona, Spain

A Gasbarrini
Department of Internal Medicine, Catholic University School of Medicine, Rome, Italy

Correspondence to: Dr S Danese, Department of Internal Medicine, Catholic University School of Medicine, L go Vita 1, 00168 Rome, Italy; sdanese@hotmail.com

Conflict of interest: None declared.

References

NOTICES

Masterclass in Crohn’s disease
A masterclass in Crohn’s disease will be held in Oxford on Wednesday 31 August 2005. This masterclass has been designed for consultants and registrars, including those who do not specialise in gastroenterology. Topics will include aetiology, differential diagnosis, and management. The course fee is £110 and board and accommodation is available at Wadham College at extra cost.

Six bursaries will be available for applicants training in gastroenterology or in research posts in British hospitals.

For further details and application forms contact: Professor Derek P Jewell, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK; tel +44 1865 224829; fax: +44 1865 790792; email: derek.jewell@ndm.ox.ac.uk; website: http://www.medicine.ox.ac.uk/gastro.

Asian Pacific Digestive Week 2005
This will be held on 25–28 September 2005 in COEX, Seoul, Korea. It is hosted by APDW 2005 Organizing Committee in conjunction with Asian Pacific Association of Gastroenterology (APAGE), Asian Pacific Society of Digestive Endoscopy (APSDE), Asian Pacific Association for the Study of the Liver (APASL), and International Society for Digestive Surgery (ISDS). The theme is "Rediscovery of Asia for gastrointestinal diseases". The abstract submission deadline is 15 June 2005 and early bird registration deadline is 30 June 2005.

For further information contact the Secretary General, Jin-Ho Kim, University of Ulsan, #1310 Hysung Olympic County II, 175-12, Chamsil-dong, Songpa-gu, Seoul 138-220, Korea; tel: +82 2 412 0673; fax: +82 2 412 0674; email: jhkm@amc.seoul.kr; website: http://www.APDW2005.org.
Diagnostic radiation exposure and cancer risk

M B Frenz and A S Mee

Gut 2005 54: 889-890
doi: 10.1136/gut.2005.066605

Updated information and services can be found at:
http://gut.bmj.com/content/54/6/889

These include:

References
This article cites 9 articles, 1 of which you can access for free at:
http://gut.bmj.com/content/54/6/889#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/